We look here at the current market for insomnia drugs, and at how it is changing in terms of putative therapeutic types. The article moves from GABAA receptor antagonists, as exemplified by sanofi-aventis' zolpidem and Sepracor's eszopiclone, which dominate the current market, to 5-HT2A receptor inverse agonists, along with Mitsubishi Tanabe Pharma's selective 5HT1A agonist MN 305, and the new approach that is offered by Neurim Pharmaceuticals' melatonin product, Circadin#174;. On the way we touch on the ongoing approval delays with Neurocrine Bioscience's non-benzodiazepine GABAA antagonist indiplon, and the announcement made in March 2007 that Merck & Co. and H. Lundbeck were discontinuing the development of gaboxadol. Products acting on melatonin receptors and the serotonin antagonists look set to have a significant impact on the insomnia market, and may well reduce the current dominance of GABAA receptor antagonists in the market.